Adenosine A2A receptors in Parkinson's disease treatment

Purinergic Signalling

Volumn 4, Issue 4, 2008, Pages 305-312

  Cieślak, Marek ^a   Komoszyński, Michał ^b   Wojtczak, Andrzej ^b  

^a WSZ Hospital   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Adenosine; Adenosine receptors; Dopamine receptors; Neuroprotection; Parkinson's disease

Indexed keywords

EID: 56549131041     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-008-9100-8     Document Type: Review

References (52)

1. 2A antagonist as novel nondopaminergic therapy for motor dysfunction in PD. Neurology 61:32-38
2. 2A receptor antagonist: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotox Res 3:545-556
3. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80:262-270
4. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67:631-647
5. Lotharius J, Dugan LL, O'Malley KL (1999) Distinct mechanisms underlie neurotoxin mediated cell death in cultured dopaminergic neurons. J Neurosci 19:1284-1293
6. Cochiolo JA, Ehsanian R, Bruck DK (2000) Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: evidence of compensatory plasticity in nigrostriatal neurons. J Neurosci Res 59:126-135
7. Romanowska M, Komoszyński M (2002) Adenosine - neurotransmitter and neuromodulator in central nervous system. Prog Biochem 48:230-238
8. Wardas J (2002) Neuroprotective role of adenosine in the CNS. Pol J Pharmacol 54:313-326
9. Zalewska-Kaszubska J (2002) Neuroprotective mechanisms of adenosine action on CNS neurons. Neurol Neurochir Pol 36:329-336
10. 2A receptors in brain. Neurology 61:12-18
11. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: From structure to function. Fisiol Rev 78:189-225
12. Dziedzicka-Wasylewska M (2004) Brain dopamine receptors-research perspectives and potential sites of regulation. Pol J Pharmacol 56:659-671
13. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432
14. 2 adenosine receptor: Selective co-expression with D2 dopamine receptors in rat striatum. Mol Brain Res 14:186-190
15. Fredholm B, Svenningsson P (2003) Adenosine-dopamine interactions. Neurology 61:5-9
16. 2 receptors induces rotation behavior in response to dopaminergic stimulation in rats. Eur J Pharmacol 257:5-6
17. 2A receptors. Neurology 61:44-48
18. 2A receptors enhance GABAergic synaptic transmission via cyclic AMP dependent mechanism in the rat globus pallidus. Brit J Pharmacol 136:296-302
19. Preston Z, Lee K, Widdowson L, Freeman TC, Dixon AK, Richardson PJ (2000) Adenosine receptor expression and function in rat striatal cholinergic interneurons. Brit J Pharmacol 130:886-890
20. 2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Brain Res Bull 64:155-164
21. Diaz-Cabiale Z, Hurd Y, Guidolin D, Finnman UB, Zoli M, Agnati LF, Vanderhaeghen JJ, Fuxe K, Ferre S (2001) Adenosine A 2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. Neuroreport 12:1831-1834
22. 2A agonist on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats. Psychopharmacology 168:299-306
23. Dawson TM, Mandir AS, Lee MK (2002) Animals models of PD: Pieces of the same puzzle? Neuron 35:219-222
24. Przedborski S, Vila M (2001) MPTP: A review of its mechanisms of neurotoxicity. Clin Neurosci Res 1:407-418
25. 2A and dopamine receptor interactions in basal gangia of dopamine denervated rats. Neurology 61:39-43
26. 2A antagonist ST1535 potentiates the effects of a threshold dose of L-Dopa in unilaterally 6-OHDA-lesioned rats. Brain Res 1133:110-114
27. Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J (1994) A novel selective adenosine A 2A antagonist with anticataleptic activity. Eur J Pharmacol 256:263-268
28. 2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513
29. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673-1677
30. 2A receptor antagonist treatment of Parkinson's disease. Neurology 6:293-296
31. 2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 47:414-426
32. 2A receptor antagonist istradefylline in advanced PD. Neurology 61:297-303
33. 2A receptor antagonist for the treatment of Parkinson's disease. Neurology 61:101-106
34. 2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats. Pol J Pharmacol 55:155-164
35. 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 189:182-188
36. 2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-Dopa in MPTP treated common marmosets. Eur J Pharmacol 546:82-87
37. Neustadt BR, Hao J, Lindo N, Greenlee WJ, Stamford AW, Tulshian D, Ongini E, Hunter J, Monopoli A, Bertorelli R, Foster C, Arik L, Lachowicz J, Ng K, Feng KI (2007) Potent, selective, and orally active adenosine A(2A) receptor antagonist: Arylpiperazine derivatives pf pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidines. Bioorg Med Chem Lett 17:1376-1380
38. 2A antagonists in PD. Neurology 58:1154-1160
39. DelleDonne K, Sonsalla P (1994) Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J Pharmacol Exp Ther 271:1320-1326
40. Ross G, Abbott R, Petrovitch H, Morens D, Grandinetti A, Tung K, Tanner C, Masaki K, Blanchette P, Curb J, Popper J, White L (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 20:2674-2679
41. Ascherio A, Zhang S, Hernan M, Kawachi I, Colditz G, Speizer F, willett W (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50:56-63
42. 2A antagonist theophylline in Parkinson's disease. Clin Neuropharmacol 25:25-31
43. 2A receptor mRNA in expression Parkinson's disease. Neurosci Lett 291:54-58
44. 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127:1075-1084
45. 2A receptors. Neurology 61:69-71
46. Chen J, Xu K, Petzer J, Staal R, Xu Y, Beilstein M, Sonsalla P, Castagnoli K, Castagnoli N, Schwarzschild M (2001) Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease. J Neuroscience 21:1-6
47. 2A adenosine receptors: An apparent paradox. Drug Dev Res 45:387-393
48. Ciruela F, Casado V, Rodrigues R, Lujan R, Burgueno J, Canals M, Borycz J, Rebola N, Goldberg S, Mallol J, Cortes A, Canela E, Lopez-Gimenez J, Miligan G, Liuis C, Cunha R, Ferre S, Franco R (2006) Presynaptic control of striatal glutamatergic neurotransmision by adenosine A1-A2A receptor heteromers. J Neuroscience 26:2080-2087
49. 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J Neurochem 89:152-164
50. Gołembiowska K, Zylewska A (2000) Effect of adenosine kinase, adenosine deaminase and transport inhibitors on striatal dopamine and stereotypy after methamphetamine administration. Neuropharmacology 39:2124-2132
51. 2A receptor antagonist, for treatment of Prkinson's disease. Expert Opin Investig Drugs 14:729-738
52. NewsRx.com (2006) Kyowa completes phase 3 studies of anti-Parkinson drug istradefylline, plans to submit NDA. Pain Cent Nervous Syst Week 2006 Apr 10